We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
- Authors
Kohan, Donald E.; Liew, Adrian; Tang, Sydney C. W.; Barratt, Jonathan; Heerspink, Hiddo J. L.
- Abstract
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Keywords: diabetic nephropathy; liver; randomized trial; type 2 diabetes EN diabetic nephropathy liver randomized trial type 2 diabetes 2410 2412 3 07/04/23 20230801 NES 230801 BACKGROUND Some endothelin receptor antagonists (ERAs), whether targeting only the endothelin A receptor or both endothelin A and B receptors, are associated with elevated markers of liver injury.[1] The hepatotoxicity has generally been modest; however, one ERA, sitaxsentan, caused serious drug-induced liver injury (DILI), resulting in fatalities.[2] The mechanism of ERA hepatotoxicity is not fully understood but probably relates, at least partly, to effects on hepatobiliary transporters and metabolism.[3] In addition, ERA chemical structure may be a factor.
- Subjects
ENDOTHELIN receptors; SODIUM-glucose cotransporters; TYPE 2 diabetes; CHRONIC kidney failure; MEDICAL personnel; LIVER; BRAIN natriuretic factor
- Publication
Diabetes, Obesity & Metabolism, 2023, Vol 25, Issue 8, p2410
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.15103